Our MISSION is to bring CRISPNA technology to market, and consolidate our CRISPNA technology for different CRISPR application as gene therapy and diagnosis.

CRISPR/Cas in Gene Therapy. In the field of gene therapy, the different CRISPR/Cas systems have become a powerful tool for the treatment of both monogenetic diseases and acquired diseases such as cancer or infectious diseases. These systems can be used to correct mutations, remove genes necessary for the disease process (receptors for infectious agents, oncogenes), replace mutated genes, or to safely introduce therapeutic genes so that they can compensate for deficiencies in cell function. GE has transformed the way in which gene therapy is approached, from being based exclusively on the introduction of exogenous genes and non-specific and uncontrolled genome modifications, to being able to precisely control the modifications that are made in the cells of the patients. CRISPR/Cas systems are currently being investigated in patients, with more than 100 clinical trials in different monogenetic diseases, cancer and infectious diseases. 5 of these trials are already in phase III, all of them for the treatment of beta-thalassemia or sickle cell disease. Another 18 are already in phase 2 for the treatment of different types of cancer and infectious diseases (COVID, AIDS) and monogenic diseases (hereditary angioderma and Leber’s disease))